Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer

Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the pancreas * Metastatic disease * Received at least two prior systemic cytotoxic chemotherapy regimens for unresectable, locally advanced or metastatic disease. * At least one of the prior systemic cytotoxic chemotherapy regimens for unresectable, locally advanced or metastatic disease must have contained gemcitabine and have met the following criteria: * Completed at least one cycle of the treatment * Received gemcitabine administered at a minimum dose of 800 mg/m2 per week in the first cycle of treatment * Progressed while receiving this gemcitabine regimen or within 3 months of completing gemcitabine * Progression was documented, * Preferentially radiologically by tumor growth or new lesions, or by * Clear symptomatic deterioration supported by at least two of the following clinical criteria: ≥ 10% worsening in KPS or ≥ 1 worsening in ECOG; increasing weakness or fatigue; progressive weight loss; new/worsening pain requiring increased pain medication; new/worsening jaundice, nausea, or vomiting; new/worsening ascites or pleural effusions; other physical or laboratory findings consistent with disease progression. * KPS \>/= 70 * Adequate bone marrow function * Adequate hepatic function * Adequate renal function Exclusion Criteria: * CNS metastatic disease * Bulky disease (any single mass \>10 cm). -\>Grade 2 nausea or vomiting, and/or signs of intestinal obstruction. * Prior external beam irradiation to a field that includes more than 30% of the red bone marrow. * Patients with clinically significant severe cardiorespiratory disease. Please consult with the clinical trial site for the full detailed list of specific inclusion/exclusion criteria.